Systematic review and meta-analysis deciphering the impact of fibrates on paraoxonase-1 status

Metabolism: Clinical and Experimental

Volumn 65, Issue 5, 2016, Pages 609-622

  Sahebkar, Amirhossein ^a,b   Hernández Aguilera, Anna ^c   Abelló, David ^c   Sancho, Elena ^c   Camps, Jordi ^c   Joven, Jorge ^c  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c HOSPITAL UNIVERSITARI SANT JOAN DE REUS   (Spain)

Author keywords

Cardiovascular risk; HDL; Hypertriglyceridemia; Lipoprotein metabolism; Oxidation

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ARYLDIALKYLPHOSPHATASE; HYPOCHOLESTEROLEMIC AGENT; PON1 PROTEIN, HUMAN;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETES MELLITUS; ENZYME ACTIVITY; HEART PROTECTION; HUMAN; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; LIPOPROTEIN METABOLISM; META ANALYSIS; METABOLIC SYNDROME X; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; ADVERSE EFFECTS; BLOOD; CARDIOVASCULAR DISEASES; CHEMISTRY; COMBINATION DRUG THERAPY; DIABETIC ANGIOPATHIES; DIABETIC CARDIOMYOPATHIES; DRUG EFFECTS; ENZYMOLOGY; HYPERLIPIDEMIAS; PATHOPHYSIOLOGY; RISK FACTOR; UPREGULATION;

ANTICHOLESTEREMIC AGENTS; ARYLDIALKYLPHOSPHATASE; CARDIOVASCULAR DISEASES; DIABETIC ANGIOPATHIES; DIABETIC CARDIOMYOPATHIES; DRUG THERAPY, COMBINATION; FIBRIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; METABOLIC SYNDROME X; RISK FACTORS; UP-REGULATION;

EID: 84962440914     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2016.01.002     Document Type: Review

References (105)

1. S. Lim, Y.M. Park, I. Sakuma, and K.K. Koh How to control residual cardiovascular risk despite statin treatment: focusing on HDL-cholesterol Int J Cardiol 166 2013 8 14
2. M. Jun, C. Foote, J. Lv, B. Neal, A. Patel, S.J. Nicholls, and et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis Lancet 375 2010 1875 1884
3. S. Lim, and R.H. Eckel Pharmacological treatment and therapeutic perspectives of metabolic syndrome Rev Endocr Metab Disord 15 2014 329 341
4. T. Gordon, W.B. Kannel, W.P. Castelli, and T.R. Dawber Lipoproteins, cardiovascular disease, and death. The Framingham study Arch Intern Med 141 1981 1128 1131
5. J.E. Hokanson, and M.A. Austin Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies J Cardiovasc Risk 3 1996 213 219
6. H.N. Ginsberg, M.B. Elam, L.C. Lovato, J.R. Crouse 3rd, L.A. Leiter, and P. Linz For the ACCORD Study Group Effects of combination lipid therapy in type 2 diabetes mellitus N Engl J Med 362 2010 1563 1574
7. C. Alonso-Villaverde, G. Aragonès, R. Beltrán-Debón, L. Fernández-Sender, A. Rull, J. Camps, and et al. Treatment of hypertriglyceridemia and HIV: fenofibrate-induced changes in the expression of chemokine genes in circulating leukocytes AIDS Res Ther 6 2009 10.1186/1742-6405-6-26
8. J. Camps, J. Marsillach, and J. Joven Pharmacological and lifestyle factors modulating serum paraoxonase-1 activity Mini Rev Med Chem 9 2009 911 920
9. B. Coll, J.P. van Wijk, S. Parra, M. Castro-Cabezas, I.M. Hoepelman, C. Alonso-Villaverde, and et al. Effects of rosiglitazone and metformin on postprandial paraoxonase-1 and monocyte chemoattractant protein-1 in human immunodeficiency virus-infected patients with lipodystrophy Eur J Pharmacol 544 2006 104 110
10. D. Abelló, E. Sancho, J. Camps, and J. Joven Exploring the role of paraoxonases in the pathogenesis of coronary artery disease: a systematic review Int J Mol Sci 15 2014 20997 21010
11. V.M. Alla, V. Agrawal, A. Denazareth, S. Mohiuddin, S. Ravilla, and M. Rendell A reappraisal of the risks and benefits of treating to target with cholesterol lowering drugs Drugs 73 2013 1025 1054
12. T. Bacchetti, S. Masciangelo, T. Armeni, V. Bicchiega, and G. Ferretti Glycation of human high density lipoprotein by methylglyoxal: effect on HDL-paraoxonase activity Metabolism 63 2014 307 311
13. M. Aviram, M. Rosenblat, C.L. Bisgaier, and R.S. Newton Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation Atherosclerosis 138 1998 271 280
14. M. Rosenblat, S. Ward, N. Volkova, T. Hayek, and M. Aviram VLDL triglycerides inhibit HDL-associated paraoxonase 1 (PON1) activity: in vitro and in vivo studies Biofactors 38 2012 292 299
15. A. García-Heredia, J. Marsillach, A. Rull, I. Triguero, I. Fort, B. Mackness, and et al. Paraoxonase-1 inhibits oxidized low-density lipoprotein-induced metabolic alterations and apoptosis in endothelial cells: a nondirected metabolomic study Mediators Inflamm 2013 10.1155/2013/156053
16. S.M. Grundy, H.B. Brewer Jr., J.I. Cleeman, S.C. Smith Jr., and C. Lenfant Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition Circulation 109 2004 433 438
17. G. Ruotolo, and B.V. Howard Dyslipidemia of the metabolic syndrome Curr Cardiol Rep 4 2002 494 500
18. L.F. Van Gaal, I.L. Mertens, and C.E. De Block Mechanisms linking obesity with cardiovascular disease Nature 444 2006 875 880
19. J.K. Taylor, E.P. Plaisance, A.J. Mahurin, M.L. Mestek, J. Moncada-Jimenez, and P.W. Grandjean Paraoxonase responses to exercise and niacin therapy in men with metabolic syndrome Redox Rep 20 2015 42 48
20. N. Ferré, J. Camps, J. Fernández-Ballart, V. Arija, M.M. Murphy, S. Ceruelo, and et al. Regulation of serum paraoxonase activity by genetic, nutritional, and lifestyle factors in the general population Clin Chem 49 2003 1491 1497
21. A. Rull, R. García, L. Fernández-Sender, R. Beltrán-Debón, G. Aragonès, J.M. Alegret, and et al. The role of combined assessment of defense against oxidative stress and inflammation in the evaluation of peripheral arterial disease Curr Mol Med 11 2011 453 464
22. L.G. Costa, G. Giordano, T.B. Cole, J. Marsillach, and C.E. Furlong Paraoxonase 1 (PON1) as a genetic determinant of susceptibility to organophosphate toxicity Toxicology 307 2013 115 122
23. J. Marsillach, B. Mackness, M. Mackness, F. Riu, R. Beltrán, J. Joven, and et al. Immunohistochemical analysis of paraoxonases-1, 2, and 3 expression in normal mouse tissues Free Radic Biol Med 45 2008 146 157
24. B. Mackness, R. Beltrán-Debón, G. Aragonès, J. Joven, J. Camps, and M. Mackness Human tissue distribution of paraoxonases 1 and 2 mRNA IUBMB Life 62 2010 480 482
25. O. Khersonsky, and D.S. Tawfik Structure-reactivity studies of serum paraoxonase PON1 suggest that its native activity is lactonase Biochemistry 44 2005 6371 6382
26. O. Khersonsky, and D.S. Tawfik Chromogenic and fluorogenic assays for the lactonase activity of serum paraoxonases Chembiochem 7 2006 49 53
27. J. Camps, J. Marsillach, and J. Joven The paraoxonases: role in human diseases and methodological difficulties in measurement Crit Rev Clin Lab Sci 46 2009 83 106
28. D. Hine, B. Mackness, and M. Mackness Coincubation of PON1, APO A1, and LCAT increases the time HDL is able to prevent LDL oxidation IUBMB Life 64 2012 157 161
29. J. Camps, A. García-Heredia, A. Rull, C. Alonso-Villaverde, G. Aragonès, R. Beltrán-Debón, and et al. PPARs in regulation of paraoxonases: control of oxidative stress and inflammation pathways PPAR Res 2012 10.1155/2012/616371
30. Y.R. Li, H. Zhu, M. Kauffman, I. Danelisen, H.P. Misra, Y. Ke, and et al. Paraoxonases function as unique protectors against cardiovascular diseases and diabetes: updated experimental and clinical data Exp Biol Med 239 2014 899 906
31. N. Martinelli, L. Consoli, D. Girelli, E. Grisol, R. Corrocher, and O. Olivieri Paraoxonases: ancient substrate hunters and their evolving role in ischemic heart disease Adv Clin Chem 59 2013 65 100
32. J. Camps, E. Rodríguez-Gallego, A. García-Heredia, I. Triguero, M. Riera-Borrull, A. Hernández-Aguilera, and et al. Paraoxonases and chemokine (C-C motif) ligand-2 in noncommunicable diseases Adv Clin Chem 63 2014 247 308
33. D. Moher, A. Liberati, J. Tetzlaff, D.G. Altman, and PRISMA Group Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement BMJ 339 2009 b2535
34. A. Booth Brimful of STARLITE: toward standards for reporting literature searches J Med Libr Assoc 94 2006 421 429
35. P.N. Durrington, M.I. Mackness, D. Bhatnagar, K. Julier, H. Prais, S. Arrol, and et al. Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia Atherosclerosis 138 1998 217 225
36. C.B. Begg, and M. Mazumdar Operating characteristics of a rank correlation test for publication bias Biometrics 50 1994 1088 1101
37. H.C. van Houwelingen, L.R. Arends, and T. Stijnen Advanced methods in meta-analysis: multivariate approach and meta-regression Stat Med 21 2002 589 624
38. M. Egger, G.D. Smith, and A.N. Phillips Meta-analysis: principles and procedures BMJ 315 1997 1533 1537
39. S.P. Hozo, B. Djulbegovic, and I. Hozo Estimating the mean and variance from the median, range, and the size of a sample BMC Med Res Methodol 5 2005 13
40. M. Borenstein, and J.P. Higgins Meta-analysis and subgroups Prev Sci 14 2013 134 143
41. Y. Zhou, and N. Dendukuri Statistics for quantifying heterogeneity in univariate and bivariate meta-analyses of binary data: the case of meta-analyses of diagnostic accuracy Stat Med 33 2014 2701 2717
42. A. Sahebkar, J. Rathouska, L.E. Simental-Mendía, and P. Nachtigal Statin therapy and plasma cortisol concentrations: a systematic review and meta-analysis of randomized placebo-controlled trials Pharmacol Res 103 2015 17 25
43. G. Derosa, P. Maffioli, and A. Sahebkar Plasma uric acid concentrations are reduced by fenofibrate: a systematic review and meta-analysis of randomized placebo-controlled trials Pharmacol Res 102 2015 63 70
44. Higgins JPT, and S. Green Cochrane handbook for systematic reviews of interventions. Version 5.0.2 2009 The Cochrane Collboration London
45. A.P. Agouridis, V. Tsimihodimos, T.D. Filippatos, A.A. Dimitriou, C.C. Tellis, M.S. Elisaf, and et al. The effects of rosuvastatin alone or in combination with fenofibrate or omega 3 fatty acids on inflammation and oxidative stress in patients with mixed dyslipidemia Expert Opin Pharmacother 12 2011 2605 2611
46. R.P. Dullaart, R. de Vries, H.A. Voorbij, W.J. Sluiter, and A. van Tol Serum paraoxonase-1 activity is unaffected by short-term administration of simvastatin, bezafibrate, and their combination in type 2 diabetes mellitus Eur J Clin Invest 39 2009 200 203
47. W. Phuntuwate, C. Suthisisang, B. Koanantakul, P. Chaloeiphap, M. Mackness, and B. Mackness Effect of fenofibrate therapy on paraoxonase1 status in patients with low HDL-C levels Atherosclerosis 196 2008 122 128
48. G. Paragh, I. Seres, M. Harangi, A. Erdei, M. Audikovszky, L. Debreczeni, and et al. Ciprofibrate increases paraoxonase activity in patients with metabolic syndrome Br J Clin Pharmacol 61 2006 694 701
49. V. Tsimihodimos, A. Kakafika, A.P. Tambaki, E. Bairaktari, M.J. Chapman, M. Elisaf, and et al. Fenofibrate induces HDL-associated PAF-AH but attenuates enzyme activity associated with apoB-containing lipoproteins J Lipid Res 44 2003 927 934
50. G. Paragh, I. Seres, M. Harangi, Z. Balogh, L. Ilyés, J. Boda, and et al. The effect of micronised fenofibrate on paraoxonase activity in patients with coronary heart disease Diabetes Metab 29 2003 613 618
51. Z. Balogh, I. Seres, M. Harangi, P. Kovács, G. Kakuk, and G. Paragh Gemfibrozil increases paraoxonase activity in type 2 diabetic patients. A new hypothesis of the beneficial action of fibrates? Diabetes Metab 27 2001 604 610
52. G. Paragh, Z. Balogh, I. Seres, M. Harangi, J. Boda, and P. Kovács Effect of gemfibrozil on HDL-associated serum paraoxonase activity and lipoprotein profile in patients with hyperlipidaemia Clin Drug Investig 19 2000 277 282
53. P. Macaskill, S.D. Walter, and L. Irwig A comparison of methods to detect publication bias in meta-analysis Stat Med 20 2001 641 654
54. S. Duval, and R. Tweedie Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis Biometrics 56 2000 455 463
55. M.S. Rosenberg The file-drawer problem revisited: a general weighted method for calculating fail-safe numbers in meta-analysis Evolution 59 2005 464 468
56. G. Ferretti, T. Bacchetti, and A. Sahebkar Effect of statin therapy on paraoxonase-1 status: a systematic review and meta-analysis of 25 clinical trials Prog Lipid Res 2015 [pii: S0163-7827(15)00041-7]
57. A.M. Tonkin, and L. Chen Effects of combination lipid therapy in the management of patients with type 2 diabetes mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial Circulation 122 2010 850 852
58. S.M. Grundy, J.I. Cleeman, C.N. Merz, H.B. Brewer Jr., L.T. Clark, D.B. Hunninghake, and et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines Circulation 110 2004 227 239
59. S. Adkins, K.N. Gan, M. Mody, and B.N. La Du Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes Am J Hum Genet 52 1993 598 608
60. J.G. Wheeler, B.D. Keavney, H. Watkins, R. Collins, and J. Danesh Four paraoxonase gene polymorphisms in 11212 cases of coronary heart disease and 12786 controls: meta-analysis of 43 studies Lancet 363 2004 689 695
61. G.P. Jarvik, L.S. Rozek, V.H. Brophy, T.S. Hatsukami, R.J. Richter, G.D. Schellenberg, and et al. Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1(192) or PON1(55) genotype Arterioscler Thromb Vasc Biol 20 2000 2441 2447
62. C. Gouédard, N. Koum-Besson, R. Barouki, and Y. Morel Opposite regulation of the human paraoxonase-1 gene PON-1 by fenofibrate and statins Mol Pharmacol 63 2003 945 956
63. T.M. Himbergen, L.J. van Tits, H.A. Voorbij, J. de Graaf, A.F. Stalenhoef, and M. Roest The effect of statin therapy on plasma high-density lipoprotein cholesterol levels is modified by paraoxonase-1 in patients with familial hypercholesterolaemia J Intern Med 258 2005 442 449
64. G. Aragonès, M. Guardiola, M. Barreda, J. Marsillach, R. Beltrán-Debón, A. Rull, and et al. Measurement of serum PON-3 concentration: method evaluation, reference values, and influence of genotypes in a population-based study J Lipid Res 52 2001 1055 1061
65. J. Camps, J. Joven, B. Mackness, M. Mackness, D. Tawfik, D. Draganov, and et al. Paraoxonase-1 and clopidogrel efficacy Nat Med 17 2011 1041 1042
66. A. Sahebkar, G.T. Chew, and G.F. Watts Recent advances in pharmacotherapy for hypertriglyceridemia Prog Lipid Res 56 2014 47 66
67. A. Sahebkar, L.E. Simental-Mendía, G.F. Watts, and J. Golledge Impact of fibrate therapy on plasma plasminogen activator inhibitor-1: a systematic review and meta-analysis of randomized controlled trials Atherosclerosis 240 2015 284 296
68. D.M. Shih, Y.R. Xia, X.P. Wang, E. Miller, L.W. Castellani, G. Subbanagounder, and et al. Combined serum paraoxonase knockout/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis J Biol Chem 275 2000 17527 17535
69. C.J. Ng, N. Bourquard, V. Grijalva, S. Hama, D.M. Shih, M. Navab, and et al. Paraoxonase-2 deficiency aggravates atherosclerosis in mice despite lower apolipoprotein-B-containing lipoproteins: anti-atherogenic role for paraoxonase-2 J Biol Chem 281 2006 29491 29500
70. D.M. Shih, J.M. Yu, L. Vergnes, N. Dali-Youcef, M.D. Champion, A. Devarajan, and et al. PON3 knockout mice are susceptible to obesity, gallstone formation, and atherosclerosis FASEB J 29 2015 1185 1197
71. O. Rozenberg, D.M. Shih, and M. Aviram Paraoxonase 1 (PON1) attenuates macrophage oxidative status: studies in PON1 transfected cells and in PON1 transgenic mice Atherosclerosis 181 2005 9 18
72. C.J. Ng, N. Bourquard, S.Y. Hama, D. Shish, V. Grijalva, M. Navab, and et al. Adenovirus-mediated expression of human paraoxonase 3 protects against the progression of atherosclerosis in apolipoprotein E-deficient mice Arterioscler Thromb Vasc Biol 27 2007 1368 1374
73. K.K. Koh, and M.J. Quon The importance of considering alternative or combination strategies for lowering LDL-C Int J Cardiol 136 2009 115 119
74. A. Sahebkar, and G.F. Watts New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes Clin Ther 35 2013 1082 1098
75. P. Barter, J. Kastelein, A. Nunn, and R. Hobbs High density lipoproteins (HDLs) and atherosclerosis: the unanswered questions Atherosclerosis 168 2003 195 211
76. T.J. Anderson, W.E. Boden, P. Desvigne-Nickens, J.L. Fleg, M.L. Kashyap, R. McBride, and et al. Safety profile of extended-release niacin in the AIM-HIGH trial N Engl J Med 371 2014 288 290
77. M.J. Landray, R. Haynes, J.C. Hopewell, S. Parish, T. Aung, J. Tomson, and et al. Effects of extended-release niacin with laropiprant in high-risk patients N Engl J Med 371 2014 203 212
78. M. Verdoia, A. Schaffer, H. Suryapranata, and G. De Luca Effects of HDL-modifiers on cardiovascular outcomes: a meta-analysis of randomized trials Nutr Metab Cardiovasc Dis 25 2015 9 23
79. R.S. Wright Recent clinical trials evaluating benefit of drug therapy for modification of HDL cholesterol Curr Opin Cardiol 28 2013 389 398
80. H. Shinkai Cholesteryl ester transfer-protein modulator and inhibitors and their potential for the treatment of cardiovascular diseases Vasc Health Risk Manag 8 2012 323 331
81. Y. Kao, K.C. Donaghue, A. Chan, B.H. Bennets, J. Knight, and M. Silink Paraoxonase gene cluster is a genetic marker for early microvascular complications in type 1 diabetes Diabet Med 19 2002 212 215
82. J.E. Noonan, A.J. Jenkins, J.X. Ma, A.C. Keech, J.J. Wang, and E.L. Lamoreux An update on the molecular actions of fenofibrate and its clinical effects on diabetic retinopathy and other microvascular end points in patients with diabetes Diabetes 62 2013 3968 3975
83. I. Kouroumichakis, N. Papanas, P. Zarogoulidis, V. Liakopoulos, E. Maltezos, and D.P. Mikhailidis Fibrates: therapeutic potential for diabetic nephropathy? Eur J Intern Med 23 2012 309 316
84. J.C. Fruchart Selective peroxisome proliferator-activated receptor α modulators (SPPARMα): the next generation of peroxisome proliferator-activated receptor α-agonists Cardiovasc Diabetol 12 2013 82
85. A. Sahebkar, G. Chew, and G.F. Watts New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease Expert Opin Pharmacother 15 2014 493 503
86. M. Guha, X. Gao, S. Jayaraman, and O. Gursky Correlation of structural stability with functional remodeling of high-density lipoproteins: the importance of being disordered Biochemistry 47 2008 11393 11397
87. Z. Ackerman, M. Oron-Herman, T. Rosenthal, O. Pappo, G. Link, B.A. Sela, and et al. Effects of amlodipine, captopril, and bezafibrate on oxidative milieu in rats with fatty liver Dig Dis Sci 53 2008 777 784
88. M. Macan, N. Vrkić, A.L. Vrdoljak, B. Radic, and V. Bradamante Effects of high sucrose diet, gemfibrozil, and their combination on plasma paraoxonase 1 activity and lipid levels in rats Acta Biochim Pol 57 2010 321 326
89. J. Bełtowski, G. Wójcicka, M. Mydlarczyk, and Jamroz The effect of peroxisome proliferator-activated receptors alpha (PPARalpha) agonist, fenofibrate, on lipid peroxidation, total antioxidant capacity, and plasma paraoxonase 1 (PON 1) activity J Physiol Pharmacol 53 2002 463 475
90. A.V. Ferreira, Z. Menezes-Garcia, E.G. Mario, H.L. Delpuerto, A.S. Martins, and L.M. Botion Increased expression of oxidative enzymes in adipose tissue following PPARα-activation Metabolism 63 4 2014 456 460
91. A. García-Heredia, E. Kensicki, R.P. Mohney, A. Rull, I. Triguero, J. Marsillach, and et al. Paraoxonase-1 deficiency is associated with severe liver steatosis in mice fed a high-fat high-cholesterol diet: a metabolomic approach J Proteome Res 12 2013 1946 1955
92. A. Devarajan, D. Shih, and S.T. Reddy Inflammation, infection, cancer and all that...the role of paraoxonases Adv Exp Med Biol 824 2014 33 41
93. A. Rull, B. Geeraert, G. Aragonès, R. Beltrán-Debón, E. Rodríguez-Gallego, A. García-Heredia, and et al. Rosiglitazone and fenofibrate exacerbate liver steatosis in a mouse model of obesity and hyperlipidemia. A transcriptomic and metabolomic study J Proteome Res 13 2014 1731 1743
94. M. Navab, S.T. Reddy, B.J. Van Lenten, and A.M. Fogelman HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms Nat Rev Cardiol 8 2011 222 232
95. R. Kones Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes Vasc Health Risk Manag 9 2013 617 670
96. B.A. Kingwell, M.J. Chapman, A. Kontush, and N.E. Miller HDL-targeted therapies: progress, failures and future Nat Rev Drug Discov 13 2014 445 464
97. S.T. Reddy, M. Navab, G.M. Anantharamaiah, and A.M. Fogelman Searching for a successful HDL-based treatment strategy Biochim Biophys Acta 184 2014 162 167
98. J.A. Menendez, T. Alarcón, and J. Joven Gerometabolites: the pseudohypoxic aging side of cancer oncometabolites Cell Cycle 13 2014 699 709
99. J.L. Mehta, Z. Bursac, M. Hauer-Jensen, C. Fort, and L.M. Fink Comparison of mortality rates in statin users versus nonstatin users in a United States veteran population Am J Cardiol 98 2006 923 928
100. Q.L. Wan, S.Q. Zheng, G.S. Wu, and H.R. Luo Aspirin extends the lifespan of Caenorhabditis elegans via AMPK and DAF-16/FOXO in dietary restriction pathway Exp Gerontol 48 2013 499 506
101. W. Linz, T. Jessen, R.H. Becker, B.A. Schölkens, and G. Wiemer Long-term ACE inhibition doubles lifespan of hypertensive rats Circulation 96 1997 3164 3172
102. I. Aslan, E. Kucuksayan, and M. Aslan Effect of insulin analog initiation therapy on LDL/HDL subfraction profile and HDL associated enzymes in type 2 diabetic patients Lipids Health Dis 12 2013 54
103. Y. Daali, J.L. Reny, and P. Fontana Role of paraoxonase-1 in CYP2C19 loss-of-function carriers Thromb Res 133 2014 519
104. S. Tuteja, and D.J. Rader Dyslipidaemia: cardiovascular prevention - end of the road for niacin? Nat Rev Endocrinol 10 2014 646 647
105. B. Zhang, J. Menzin, M. Friedman, J.R. Korn, and R.T. Burge Predicted coronary risk for adults with coronary heart disease and low HDL-C: an analysis from the US National Health and Nutrition Examination Survey Curr Med Res Opin 24 2008 2711 2717